Central Nervous System Disorders Therapeutics Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Central Nervous System Disorders Therapeutics Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
Global Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurovascular Diseases, Trauma, Mental Health {Anxiety Disorders, Epilepsy, and Others}, Degenerative Diseases {Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Cancer, and Others), by Drug Type (Analgesics, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 131.3 million in 2021, and is expected to exhibit a CAGR of 6.4% during the forecast period (2021-2028).
Get Your FREE Sample Copy of the Central Nervous System Disorders Therapeutics Report 2021
Rising cases of central nervous system (CNS) disorders is expected to drive growth of the global central nervous system disorders therapeutics market during the forecast period. For instance, according to data published by Alzheimer’s Association in 2017, around 5.5 million people in the U.S. (all ages) suffered from Alzheimer’s dementia. Similarly, according to World Alzheimer Report of 2016, around 47 million people were living with dementia worldwide, and this statistics is expected to increase by three-fold and reach 131 million by 2050. Moreover, according to Alzheimer’s disease Facts and Figures Report, in 2019, more than 5.8 million people in the U.S. were suffering from dementia associated with Alzheimer’s disease, out of which most of the patients were above the age of 75 years.
Market players are engaged in inorganic activities such as collaboration of companies, which is expected to drive growth of the global central nervous system disorders therapeutics market. For instance, in January 2019, Corbus Pharmaceuticals Holdings, Inc., a U.S. based pharmaceutical company collaborated with Kaken Pharmaceutical Co., a Japanese pharmaceutical company to commercialize its new product Lenabasum in Japan. Lenabasum is a compound used for treatment of systemic sclerosis.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/4544
Reasons to Purchase this Report
• Current and future of global Central Nervous System Disorders Therapeutics market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/4544
Global Central Nervous System Disorders Therapeutics Market – Impact of Coronavirus (COVID – 19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 186 million cases and 4.0 million deaths due to Coronavirus (COVID-19) were reported up till July 11, 2021 across the globe.
The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper the demand and supply in global central nervous system disorders therapeutics market. The COVID-19 pandemic has affected the demand and supply of global central nervous system disorders therapeutics market in three main ways; by directly affecting the production and demand of CNS disorder drugs; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets. Supply chain and manufacturing activities of neurological biomarkers in India, China, and the U.S. are disrupted due to nationwide lockdowns.
For instance, according to an article published by Clinical trial arena in January 2021, around 84% of patients suffering from severe COVID-19 infection are reported to experience some kind of cognitive impairment such as mental confusion. This study reveals that COVID-19 patients are at a higher risk of acquiring a neurological disorder such as dementia and Alzheimer’s disease. Thus, COVID-19 pandemic is expected to increase the demand of central nervous system disorders therapeutics for treatment of CNS disorders associated with COVID-19 infection.
Moreover, launch of new CNS disorder drugs and approvals is expected to drive the global central nervous system disorders therapeutics market growth. For instance, in April 2020, Neurocrine Biosciences, Inc., a U.S. based biopharmaceutical company received the U.S. Food and Drug Administration (FDA) approval for its drug Ongentys used to treat Parkinson’s disease.
Key Takeaways of the Global Central Nervous System Disorders Therapeutics Market:
- The global central nervous system disorders therapeutics market is expected to exhibit a CAGR of 6.4% over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028) owing to rising number of product launches. For instance, in October 2019, Biogen, a U.S. based biotechnology company and Alkermes plc, an Ireland based biopharmaceutical company received the U.S. FDA approval for their drug VUMERITY which is used for treatment of multiple Multiple sclerosis drugs is expected to be the fastest growing segment in the central nervous system disorders therapeutics market due to rising cases of multiple sclerosis. Furthermore, according to the national multiple sclerosis society data 2020, there are approximately 2.8 million people around the world who were suffering from multiple sclerosis in 2020.
- Some of the major players operating in the global central nervous system disorders therapeutics market include Pfizer Inc., Biogen, Otsuka Pharmaceutical Co. Ltd., Merck & Co., AstraZeneca, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Private Limited, Eli Lilly and Company, Sanofi, GlaxoSmithKline plc., and Boehringer Ingelheim International GmbH
Browse 32 Market Data Tables and 25 Figures spread through 170 Pages and in-depth TOC on Global Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurovascular Diseases, Trauma, Mental Health {Anxiety Disorders, Epilepsy, and Others}, Degenerative Diseases {Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Cancer, and Others), by Drug Type (Analgesics, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
Major Point Answered in Central Nervous System Disorders Therapeutics Market Research Study are: –
• What will the market growth rate, Overview and Analysis by Type of Central Nervous System Disorders Therapeutics market in 2026?
• What are the key factors driving, Analysis by Applications and Countries Central Nervous System Disorders Therapeutics market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Central Nervous System Disorders Therapeutics market?
• Who are Opportunities, Risk and Driving Force of Central Nervous System Disorders Therapeutics market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in Central Nervous System Disorders Therapeutics market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Central Nervous System Disorders Therapeutics market opportunities and threats faced by the vendors in the market?
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- PEST Analysis
- Industry Trends
- Pipeline Analysis
- Key Highlights
- Epidemiology
- Pricing Analysis
- Regulatory Scenario
- Global Supply Chain Analysis
- Market Dynamics
- Global Central Nervous System Disorders Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Impact of COVID-19 on Demand and Supply of Central Nervous System Disorders Therapeutics
- Impact of Covid-19 on the Central Nervous System Disorders Therapeutics Market
- Global Central Nervous System Disorders Therapeutics Market, By Disease Type, 2017-2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Neurovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Trauma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Mental Health
- Anxiety Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Epilepsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Anxiety Disorders
- Degenerative Diseases
- Alzheimer’s Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Parkinson’s Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Central Nervous System Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Alzheimer’s Disease
- Introduction
- Global Central Nervous System Disorders Therapeutics Market, By Drug Type, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Anesthetics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Anti-Parkinson Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Anti-Epileptics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Central Nervous System Disorders Therapeutics Market, By Region, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2018 – 2028
- Regional Trends
- North America
- Market Size and Forecast, By Disease Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Drug Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Disease Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Drug Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Disease Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Drug Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Disease Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Drug Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Disease Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Drug Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Disease Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Drug Type, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 – 2028 (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837